Amorphous Solid Dispersion of Niclosamide with Water-Soluble β-Cyclodextrins for Dissolution and Bioavailability Enhancement

被引:3
作者
Gupta, Deepank S. [1 ]
Kotwal, Pankul [2 ]
Nandi, Utpal [2 ]
Bharate, Sonali S. [1 ]
机构
[1] SVKMs NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Man, VL Mehta Rd,Vile Parle W, Mumbai 400056, India
[2] CSIR Indian Inst Integrat Med, Pharmacol Div, Canal Rd, Jammu 180001, India
关键词
Dissolution; hydroxypropyl-beta-cyclodextrin; niclosamide; pharmacokinetics; solubility; PHARMACEUTICAL APPLICATIONS; INCLUSION COMPLEX; DRUG-DELIVERY; FORMULATION; SOLUBILITY; ROHITUKINE;
D O I
10.1002/slct.202300492
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cyclodextrins (CDs) are cyclic oligosaccharides widely employed for the solubility enhancement of poorly water-soluble drugs. Niclosamide is a BCS class II drug for tapeworm infections and is currently under repurposing for various other indications, including COVID-19. Due to its low aqueous solubility, a high daily dose (2 g) is required for clinical efficacy. Herein, we investigate the potential of beta-cyclodextrin (beta-CD) and its sulfobutylether and hydroxypropyl derivatives for the dissolution enhancement of niclosamide. The solid dispersions were prepared by kneading the drug and cyclodextrins together by adding solvent, water: methanol (1 : 1 v/v). Among various CDs studied, 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD) in the 1: 2 molar ratio (SB-IC-N4 batch) shows the most significant improvement in water solubility of niclosamide (6.3 vs. 182 mu g/ml), resulting in 2-fold improved in-vitro dissolution. The comparative oral pharmacokinetics in Wistar rats at 50 mg/ kg produced 1.69-fold higher plasma exposure of niclosamide. The spectral characterization provided molecular insights into interactions of niclosamide with HP-beta-CD. These results suggest that the dispersion of niclosamide with HP-beta-CD aid in faster dissolution and better drug bioavailability.
引用
收藏
页数:10
相关论文
共 44 条
[1]  
ACERBI D, 1988, INT J CLIN PHARM RES, V8, P175
[2]  
Al-Hadiya Badraddin M H, 2005, Profiles Drug Subst Excip Relat Methodol, V32, P67, DOI 10.1016/S0099-5428(05)32002-8
[3]  
[Anonymous], STUDY NICLOSAMIDE MO
[4]  
[Anonymous], NICLOSAMIDE MILD MOD
[5]  
[Anonymous], NICLOSAMIDE PEDIAT P
[6]  
[Anonymous], A study to evaluate the efficacy and safety of pemigatinib versus chemotherapy in unresectable or metastatic cholangiocarcinoma (FIGHT -302)
[7]  
[Anonymous], NICLOSAMIDE ROLE DIA
[8]  
[Anonymous], 2017, Field use of molluscicides in schistosomiasis control programmes: an operational manual for programme managers
[9]  
[Anonymous], A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis, Patent No. [NCT03521232, 03521232]
[10]  
[Anonymous], EMACHMP4957472013